MARTINEZ, Calif. – ExThera Medical announced today the release of preliminary clinical study data demonstrating significantly improved survival rates among critically ill COVID-19 patients when treated with the Seraph® 100 Microbind® Affinity Blood Filter compared to contemporaneous controls. The device is being investigated under the PURIFY OBS trial facilitated by the Henry Jackson Foundation for the Advancement of Military Medicine and the Uniformed Services University of the Department of Defense.